"The
Report Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) -
Pipeline Review, H2 2016 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Global
Markets Directs, Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4
or GRM4) - Pipeline Review, H2 2016, provides in depth analysis on
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted
pipeline therapeutics.
The
report provides comprehensive information on the Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) , targeted
therapeutics, complete with analysis by indications, stage of
development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted
therapeutics development and features dormant and discontinued
projects.
View Report @
http://www.marketresearchreports.biz/analysis/928075
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
-
The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or
MGLUR4 or GRM4) targeted therapeutics under development by companies
and universities/research institutes based on information derived
from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Metabotropic Glutamate
Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and
enlists all their major and minor projects
-
The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or
MGLUR4 or GRM4) targeted therapeutics based on mechanism of action
(MoA), route of administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics
Download
Sample Copy Of this Report @
http://www.marketresearchreports.biz/sample/sample/928075
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Table
of Content
Table
of Contents 2
List
of Tables 4
List
of Figures 4
Introduction
5
Global
Markets Direct Report Coverage 5
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Overview 6
Therapeutics
Development 7
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under
Development by Stage of Development 7
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under
Development by Therapy Area 8
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under
Development by Indication 9
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Products
Glance 10
Early
Stage Products 10
Unknown
Stage Products 11
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under
Development by Companies 12
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under
Development by Universities/Institutes 14
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics
Assessment 16
Assessment
by Monotherapy/Combination Products 16
Assessment
by Mechanism of Action 17
Assessment
by Route of Administration 19
Assessment
by Molecule Type 20
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved
in Therapeutics Development 21
Addex
Therapeutics Ltd 21
Prexton
Therapeutics SA 22
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles 23
ADX-88178
- Drug Profile 23
Product
Description 23
Mechanism
Of Action 23
R&D
Progress 23
JBPOS-0101
- Drug Profile 26
Product
Description 26
Mechanism
Of Action 26
R&D
Progress 26
PXT-2331
- Drug Profile 27
Product
Description 27
Mechanism
Of Action 27
R&D
Progress 27
Small
Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile 28
Product
Description 28
Mechanism
Of Action 28
R&D
Progress 28
VU-0418506
- Drug Profile 29
Product
Description 29
Mechanism
Of Action 29
R&D
Progress 29
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Projects 30
Metabotropic
Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Featured News &
Press Releases 31
Oct
11, 2016: Addex Initiates New Study in Collaboration with US National
Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of
Cocaine Addiction 31
Sep
19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1
clinical trial 31
Jun
13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical
Models of Neurodegenerative and Psychiatric Diseases 32
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment